ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

H3 K27M
Glioma

Interventions

DRUG: Dordaviprone (ONC201)
DRUG: Dordaviprone (ONC201) + Placebo
OTHER: Placebo

Sponsor

Jazz Pharmaceuticals

Collaborators

[object Object]